Based out of Enschede, the Netherlands, Sencure, a company that is focused on medical devices for monitoring and diagnostic purposes, announced on Wednesday, July 12, that it has secured €5M in a fresh round of funding.
Sencure says the money will be utilised to accelerate the industrialisation of its flagship product, the SNCE-800 chip, which is recognised for its capacity to monitor superior electrophysiological signals with ‘exceptional’ power efficiency.
Dick van Waes, CEO of Sencure, says, “With this funding, we can accelerate the industrialisation process of our SNCE-800 chip and bring biosensor solutions to market faster. This investment is a testament to the hard work and dedication of our exceptional team.”
Investors supporting Sencure
The round was led by Cottonwood Technology Fund, a VC firm that backs early-stage tech companies with the potential for global impact. The firm, with a focus on deeptech and innovation, assists companies in scaling their operations and revolutionising their respective sectors.
The round also saw participation from the Northern Netherlands Investment Agency (NOM), a deeptech investor recognised for helping early-stage tech companies with revolutionary concepts, and current deeptech and medtech investor Lumana Invest.
Alain le Loux, Partner at Cottonwood Technology Fund, says, “We are thrilled to lead this investment round for Sencure. Their groundbreaking biosensor chip technology has the potential to revolutionise remote patient monitoring and reshape the healthcare landscape.”
Integrated biosensor technology
Founded in 2021, Sencure claims to be a pioneering firm that specialises in the creation of chips for medical wearable biosensors.
The company originates from ItoM Medical BV, a company founded in 2018 as the medical branch of chip development company Semiconductor Ideas to the Market (ItoM) BV.
Sencure aims to change the healthcare business by delivering high-quality and comfortable solutions for remote patient monitoring with a focus on integrating “cutting-edge” technology with a “superior” power economy.
The company says, “We believe that using advanced chip technology, Sencure can improve the quality of medical wearable devices, increase the speed of development of medical devices and reduce the size of such devices.”
According to Sencure, its SNCE-800 microprocessor marks a significant achievement, allowing medical wearable biosensors to collect high-quality electrophysiological data like ECG and EEG while consuming minimum power.
This novel technology has the potential for improving patient care by providing healthcare practitioners with crucial insights into physiological states without compromising comfort or battery life.
Sencure products are used in measuring a wide range of bioelectrical data such as vital activities in people’s hearts, breathing and brain.
01
How Leipzig became a hub for energy and medical tech startups with IRL and SpinLab support